Cargando…

Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy

IMPORTANCE: Benign prostatic hyperplasia (BPH) in older men can cause lower urinary tract symptoms (LUTS), which are increasingly managed with medications. Frailty may contribute to both symptom progression and serious adverse events (SAEs), shifting the balance of benefits and harms of drug therapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bauer, Scott R., Walter, Louise C., Ensrud, Kristine E., Suskind, Anne M., Newman, John C., Ricke, William A., Liu, Teresa T., McVary, Kevin T., Covinsky, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613596/ https://www.ncbi.nlm.nih.gov/pubmed/34817584 http://dx.doi.org/10.1001/jamanetworkopen.2021.34427

Ejemplares similares

Association of Frailty Index with Clinical BPH Progression and Serious Adverse Events: the MTOPS Trial
por: Bauer, Scott, et al.
Publicado: (2021)

Water vapor thermal therapy to alleviate catheter-dependent urinary retention secondary to benign prostatic hyperplasia
por: McVary, Kevin T., et al.
Publicado: (2019)

Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia
por: McVary, Kevin T., et al.
Publicado: (2021)

Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations
por: Lee, Lulu K, et al.
Publicado: (2016)

ASSOCIATION OF LOWER URINARY TRACT SYMPTOMS WITH INCIDENT FRAILTY AND MORTALITY AMONG OLDER COMMUNITY-DWELLING MEN
por: Cawthon, Peggy, et al.
Publicado: (2022)

Putting Patients Ahead by Leaving Nothing Behind: An Emerging Treatment Paradigm in Minimally Invasive Surgical Therapy for Benign Prostatic Hyperplasia
por: McVary, Kevin T, et al.
Publicado: (2021)

Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Welliver, Charles, et al.
Publicado: (2022)

Water vapor thermal therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: Systematic review and meta-analysis
por: Miller, Larry E., et al.
Publicado: (2020)

Preface on current topics in men’s health
por: Welliver, Charles, et al.
Publicado: (2016)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

SUN-747 Steroid Hormone Metabolism Mediated Racial Disparity in Men with Benign Prostatic Hyperplasia
por: Liu, Teresa T, et al.
Publicado: (2020)

A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia
por: Chughtai, Bilal, et al.
Publicado: (2022)

Frailty Phenotype and Healthcare Costs in Older Community-Dwelling Men: The MrOS study
por: Ensrud, Kristine, et al.
Publicado: (2020)

Automated Electronic Frailty Index–Identified Frailty Status and Associated Postsurgical Adverse Events
por: Khanna, Ashish K., et al.
Publicado: (2023)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Frailty as a risk marker of adverse lower urinary symptom outcomes in patients with benign prostatic hyperplasia undergoing transurethral resection of prostate
por: Ren, Xiang, et al.
Publicado: (2023)

Hepatic Focal Nodular Hyperplasia: A Benign Incidentaloma or a Marker of Serious Hepatic Disease?
por: Muguti, G., et al.
Publicado: (1992)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Both pre-frailty and frailty increase healthcare utilization and adverse health outcomes in patients with type 2 diabetes mellitus
por: Chao, Chia-Ter, et al.
Publicado: (2018)

Technique considerations and complication management in transurethral resection of the prostate and photoselective vaporization of the prostate
por: Welliver, Charles, et al.
Publicado: (2017)

Leveraging Existing Data from CMS-Linked Cohort Studies for the Advancement and Translation of Frailty Research
por: Xue, Qian-Li, et al.
Publicado: (2020)

Aquablation in men with benign prostate hyperplasia: A systematic review and meta-analysis
por: Chen, David C., et al.
Publicado: (2023)

The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia
por: Sullivan, Michael J, et al.
Publicado: (2002)

Frailty as a Risk Factor for Cardiovascular Versus Noncardiovascular Mortality in Older Men: Results From the MrOS Sleep (Outcomes of Sleep Disorders in Older Men) Study
por: Adabag, Selcuk, et al.
Publicado: (2018)

Low-Dose Methotrexate and Serious Adverse Events Among Older Adults With Chronic Kidney Disease
por: Muanda, Flory T., et al.
Publicado: (2023)

Benign Prostatic Hyperplasia
Publicado: (2015)

Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer
por: Winn, Aaron N., et al.
Publicado: (2020)

Bacteriology of Urine Specimens Obtained from Men with Symptomatic Benign Prostatic Hyperplasia
por: Agbugui, Jude Orumuah, et al.
Publicado: (2016)

Ultrasonographic Intravesical Prostatic Protrusion in Men with Benign Prostatic Hyperplasia in Southwest Nigeria
por: Okedere, Tolulope Adebayo, et al.
Publicado: (2023)

Characterization of Fibrillar Collagens and Extracellular Matrix of Glandular Benign Prostatic Hyperplasia Nodules
por: Bauman, Tyler M., et al.
Publicado: (2014)

Frailty Phenotype and Healthcare Costs in Women in Late Life: The SOF study
por: Langsetmo, Lisa, et al.
Publicado: (2020)

The association between antihypertensive treatment and serious adverse events by age and frailty: A cohort study
por: Sheppard, James P., et al.
Publicado: (2023)

Men’s preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment
por: Mankowski, Colette, et al.
Publicado: (2016)

Association of Higher-Dose Fluoroquinolone Therapy With Serious Adverse Events in Older Adults With Advanced Chronic Kidney Disease
por: Muanda, Flory Tsobo, et al.
Publicado: (2022)

Ejaculatory dysfunction in the treatment of lower urinary tract symptoms
por: DeLay, Kenneth Jackson, et al.
Publicado: (2016)

Sebaceous hyperplasia: systemic treatment with isotretinoin()
por: Tagliolatto, Sandra, et al.
Publicado: (2015)

Penile Glans Necrosis following Prostatic Artery Embolization for the Treatment of Benign Prostatic Hyperplasia: A Rare but Serious Complication
por: Chung, Eric
Publicado: (2021)

Impact of Benign Prostatic Hyperplasia Pharmacological Treatment on Transrectal Prostate Biopsy Adverse Effects
por: Zamuner, Marina, et al.
Publicado: (2014)

Ramelteon combined with an α(1)-blocker decreases nocturia in men with benign prostatic hyperplasia
por: Kawahara, Takashi, et al.
Publicado: (2013)

Immunohistochemical analysis of estrogen receptors in prostate and clinical correlation in men with benign prostatic hyperplasia
por: Gangkak, Goto, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d3eos91eb92rrb497pa3t3kh46